Effect of Doxycycline in Patients of Moderate to Severe Chronic Obstructive Pulmonary Disease with Stable Symptoms

Overview

Journal Ann Thorac Med

Specialty Pulmonary Medicine

Date 2011 Oct 7

PMID 21977068

Citations 14

Authors

Prashant S Dalvi

Anil Singh

Hiren R Trivedi

Feroz D Ghanchi

Dinesh M Parmar

Suresh D Mistry

Affiliations

Soon will be listed here.

Abstract

Background: The protease-antiprotease hypothesis proposes that inflammatory cells and oxidative stress in chronic obstructive pulmonary disease (COPD) produce increased levels of proteolytic enzymes (neutrophil elastase, matrix metalloproteinases [MMP]) which contribute to destruction of parenchyma resulting in progressive decline in forced expiratory volume in one second. Doxycycline, a tetracycline analogue, possesses anti-inflammatory properties and inhibits MMP enzymes.

Objectives: To assess the effect of 4 weeks doxycycline in a dose of 100 mg once a day in patients of moderate to severe COPD with stable symptoms.

Methods: In an interventional, randomized, observer-masked, parallel study design, the effect of doxycycline (100 mg once a day for 4 weeks) was assessed in patients of COPD having stable symptoms after a run-in period of 4 weeks. The study participants in reference group did not receive doxycycline. The parameters were pulmonary functions, systemic inflammation marker C-reactive protein (CRP), and medical research council (MRC) dyspnea scale. Use of systemic corticosteroids or antimicrobial agents was not allowed during the study period.

Results: A total of 61 patients completed the study (31 patients in doxycycline group and 30 patients in reference group). At 4 weeks, the pulmonary functions significantly improved in doxycycline group and the mean reduction in baseline serum CRP was significantly greater in doxycycline group as compared with reference group. There was no significant improvement in MRC dyspnea scale in both groups at 4 weeks.

Conclusion: The anti-inflammatory and MMP-inhibiting property of doxycycline might have contributed to the improvement of parameters in this study.

Citing Articles

"Pleiotropic" Effects of Antibiotics: New Modulators in Human Diseases.

Airola C, Severino A, Spinelli I, Gasbarrini A, Cammarota G, Ianiro G Antibiotics (Basel). 2025; 13(12.

PMID: 39766566 PMC: 11727521. DOI: 10.3390/antibiotics13121176.

Elastin-targeted nanoparticles delivering doxycycline mitigate cytokine storm and reduce immune cell infiltration in LPS-mediated lung inflammation.

Arora S, Vyavahare N PLoS One. 2023; 18(6):e0286211.

PMID: 37267267 PMC: 10237374. DOI: 10.1371/journal.pone.0286211.

Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model.

Siregar O, Lelo A, Rahyussalim A, Ilyas S, Benny , Kurniawati T Biomed Res Int. 2023; 2023:7421325.

PMID: 36743515 PMC: 9897918. DOI: 10.1155/2023/7421325.

Cigarette Smoke Exposure Induces Neurocognitive Impairments and Neuropathological Changes in the Hippocampus.

Dobric A, De Luca S, Seow H, Wang H, Brassington K, Chan S Front Mol Neurosci. 2022; 15:893083.

PMID: 35656006 PMC: 9152421. DOI: 10.3389/fnmol.2022.893083.

Ebselen prevents cigarette smoke-induced cognitive dysfunction in mice by preserving hippocampal synaptophysin expression.

De Luca S, Brassington K, Chan S, Dobric A, Mou K, Seow H J Neuroinflammation. 2022; 19(1):72.

PMID: 35351173 PMC: 8966248. DOI: 10.1186/s12974-022-02432-y.

References

Man S, Connett J, Anthonisen N, Wise R, Tashkin D, Sin D . C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006; 61(10):849-53. PMC: 2104755. DOI: 10.1136/thx.2006.059808. View

Finlay G, Russell K, McMAHON K, DArcy E, Masterson J, Fitzgerald M . Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997; 52(6):502-6. PMC: 1758576. DOI: 10.1136/thx.52.6.502. View

Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J . Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54(7):581-6. PMC: 1745516. DOI: 10.1136/thx.54.7.581. View

Skulason S, Holbrook W, Kristmundsdottir T . Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers. Acta Odontol Scand. 2008; 67(1):25-9. DOI: 10.1080/00016350802526559. View

Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J . Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003; 139(4):459-64. DOI: 10.1001/archderm.139.4.459. View

Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T . Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 158(4):1185-9. DOI: 10.1164/ajrccm.158.4.9802091. View

Smieja M, MacPherson D, Kean W, Schmuck M, Goldsmith C, Buchanan W . Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann Rheum Dis. 2001; 60(12):1088-94. PMC: 1753446. DOI: 10.1136/ard.60.12.1088. View

Dahl M, Vestbo J, Lange P, Bojesen S, Tybjaerg-Hansen A, Nordestgaard B . C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 175(3):250-5. DOI: 10.1164/rccm.200605-713OC. View

Koivunen A, Maisi P, Konttinen Y, Prikk K, SANDHOLM M . Collagenolytic activity and its sensitivity to doxycycline inhibition in tracheal aspirates of horses with chronic obstructive pulmonary disease. Acta Vet Scand. 1997; 38(1):9-16. PMC: 8057019. View

10.

Belvisi M, Bottomley K . The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?. Inflamm Res. 2003; 52(3):95-100. DOI: 10.1007/s000110300020. View

11.

Cazzola M, MacNee W, Martinez F, Rabe K, Franciosi L, Barnes P . Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31(2):416-69. DOI: 10.1183/09031936.00099306. View

12.

Raza M, Ballering J, Hayden J, Robbins R, Hoyt J . Doxycycline decreases monocyte chemoattractant protein-1 in human lung epithelial cells. Exp Lung Res. 2006; 32(1-2):15-26. DOI: 10.1080/01902140600691399. View

13.

Sapadin A, Fleischmajer R . Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54(2):258-65. DOI: 10.1016/j.jaad.2005.10.004. View

14.

Fiotti N, Altamura N, Moretti M, Wassermann S, Zacchigna S, Farra R . Short term effects of doxycycline on matrix metalloproteinases 2 and 9. Cardiovasc Drugs Ther. 2008; 23(2):153-9. DOI: 10.1007/s10557-008-6150-7. View

15.

Sochor M, Richter S, Schmidt A, Hempel S, Hopt U, Keck T . Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitis-associated lung injury. Digestion. 2009; 80(2):65-73. DOI: 10.1159/000212080. View

16.

Ciancio S, Ashley R . Safety and efficacy of sub-antimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res. 1999; 12(2):27-31. DOI: 10.1177/08959374980120011501. View

17.

Anthonisen N, Manfreda J, Warren C, Hershfield E, Harding G, Nelson N . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2):196-204. DOI: 10.7326/0003-4819-106-2-196. View

18.

Golub L, Suomalainen K, Sorsa T . Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent. 1992; 2:80-90. View

19.

Doroszko A, Hurst T, Polewicz D, Sawicka J, Fert-Bober J, Johnson D . Effects of MMP-9 inhibition by doxycycline on proteome of lungs in high tidal volume mechanical ventilation-induced acute lung injury. Proteome Sci. 2010; 8:3. PMC: 2824689. DOI: 10.1186/1477-5956-8-3. View

20.

Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S . Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med. 1999; 159(6):1985-91. DOI: 10.1164/ajrccm.159.6.9809043. View